GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » Beneish M-Score

Inogen (Inogen) Beneish M-Score : -3.61 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Inogen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.61 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Inogen's Beneish M-Score or its related term are showing as below:

INGN' s Beneish M-Score Range Over the Past 10 Years
Min: -3.61   Med: -2.69   Max: -1.29
Current: -3.61

During the past 13 years, the highest Beneish M-Score of Inogen was -1.29. The lowest was -3.61. And the median was -2.69.


Inogen Beneish M-Score Historical Data

The historical data trend for Inogen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen Beneish M-Score Chart

Inogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.00 -3.18 -3.07 -1.29 -3.61

Inogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 -2.30 -2.28 -3.06 -3.61

Competitive Comparison of Inogen's Beneish M-Score

For the Medical Devices subindustry, Inogen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inogen's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Inogen's Beneish M-Score falls into.



Inogen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Inogen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7969+0.528 * 1.014+0.404 * 1.6967+0.892 * 0.8368+0.115 * 1.3008
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3234+4.679 * -0.204752-0.327 * 1.3242
=-3.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $42.9 Mil.
Revenue was 75.896 + 83.967 + 83.635 + 72.162 = $315.7 Mil.
Gross Profit was 28.158 + 33.764 + 34.044 + 30.733 = $126.7 Mil.
Total Current Assets was $207.1 Mil.
Total Assets was $326.2 Mil.
Property, Plant and Equipment(Net PPE) was $70.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $18.2 Mil.
Selling, General, & Admin. Expense(SGA) was $182.4 Mil.
Total Current Liabilities was $72.5 Mil.
Long-Term Debt & Capital Lease Obligation was $18.3 Mil.
Net Income was -26.555 + -45.719 + -9.826 + -20.349 = $-102.4 Mil.
Non Operating Income was 0.292 + -33.292 + 0.337 + 0.237 = $-32.4 Mil.
Cash Flow from Operations was -3.148 + 2.185 + 4.03 + -6.301 = $-3.2 Mil.
Total Receivables was $64.4 Mil.
Revenue was 88.091 + 105.389 + 103.376 + 80.385 = $377.2 Mil.
Gross Profit was 29.471 + 42.798 + 46.258 + 35.006 = $153.5 Mil.
Total Current Assets was $304.6 Mil.
Total Assets was $405.0 Mil.
Property, Plant and Equipment(Net PPE) was $64.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $23.5 Mil.
Selling, General, & Admin. Expense(SGA) was $164.7 Mil.
Total Current Liabilities was $65.3 Mil.
Long-Term Debt & Capital Lease Obligation was $19.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(42.91 / 315.66) / (64.351 / 377.241)
=0.135937 / 0.170583
=0.7969

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(153.533 / 377.241) / (126.699 / 315.66)
=0.406989 / 0.401378
=1.014

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (207.067 + 70.654) / 326.194) / (1 - (304.645 + 64.922) / 405.041)
=0.148602 / 0.087581
=1.6967

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=315.66 / 377.241
=0.8368

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(23.514 / (23.514 + 64.922)) / (18.152 / (18.152 + 70.654))
=0.265887 / 0.204401
=1.3008

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(182.351 / 315.66) / (164.672 / 377.241)
=0.577682 / 0.436517
=1.3234

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18.27 + 72.496) / 326.194) / ((19.764 + 65.349) / 405.041)
=0.278258 / 0.210134
=1.3242

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-102.449 - -32.426 - -3.234) / 326.194
=-0.204752

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Inogen has a M-score of -3.61 suggests that the company is unlikely to be a manipulator.


Inogen (Inogen) Business Description

Traded in Other Exchanges
Address
301 Coromar Drive, Goleta, CA, USA, 93117
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.
Executives
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer officer: EVP, Chief Medical Officer C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer officer: EVP, Gen. Counsel & Secretary C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein director 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone director 130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King director C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider officer: EVP, CFO and Treasurer C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M director 1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter officer: EVP, CFO and Treasurer 301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger director, officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein officer: See Remarks 326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor officer: Vice President, Engineering 326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora director C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers officer: Vice President, Marketing 326 BOLLAY DRIVE, GOLETA CA 93117